{"id":"placebo-of-da-2803","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL576533","moleculeType":"Small molecule","molecularWeight":"455.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo of DA-2803 is an inert control product designed to match the appearance and administration route of the active DA-2803 drug. It serves as a blinded comparator in clinical studies to isolate the true therapeutic effect of DA-2803 from placebo response and natural disease progression.","oneSentence":"A placebo formulation containing no active pharmaceutical ingredient, used as a control comparator in clinical trials.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:01:12.571Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05957380","phase":"PHASE4","title":"Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2023-03-20","conditions":"Hepatitis B","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo of DA-2803","genericName":"Placebo of DA-2803","companyName":"Dong-A ST Co., Ltd.","companyId":"dong-a-st-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}